Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

8.45USD
26 May 2017
Change (% chg)

-- (--)
Prev Close
$8.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
78,372
52-wk High
$14.60
52-wk Low
$5.50

STML.OQ

Chart for STML.OQ

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.16
Market Cap(Mil.): $212.23
Shares Outstanding(Mil.): 25.12
Dividend: --
Yield (%): --

Financials

  STML.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -2.31 -- --
ROI: -50.27 -8.48 -5.42
ROE: -50.43 -11.31 -4.68

BRIEF-Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 BPDCN trial

* Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 bpdcn trial at upcoming European Hematology Association (EHA) meeting Source text for Eikon: Further company coverage:

May 18 2017

BRIEF-Stemline Therapeutics Q1 loss per share $0.67

* Stemline therapeutics reports first quarter 2017 financial results

May 10 2017

BRIEF-Stemline Therapeutics reports completion of enrollment in stage 3 sl-401 pivotal trial in BPDCN

* Stemline Therapeutics announces completion of enrollment in stage 3 of the sl-401 pivotal trial in bpdcn

Mar 23 2017

BRIEF-Stemline Therapeutics Q4 loss per share $0.56

* Stemline therapeutics reports fourth quarter 2016 financial results

Mar 16 2017

BRIEF-Stemline Therapeutics provides update on pivotal BPDCN trial

* Stemline therapeutics provides update on pivotal bpdcn trial

Feb 02 2017

More From Around the Web

Competitors

Earnings vs. Estimates